Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by nodaytraderon Dec 19, 2023 2:40pm
124 Views
Post# 35792243

Today’s Trading

Today’s Trading Desjardins is active in trading today and is pre-eminent in the depth chart, suggesting that it is interested in buying but only at progressively lower prices.I find that puzzling!

A Google search told me that low share prices make it more difficult for the listed company to raise funds. In Algernon's case, it would hinder the development of treatments for those suffering from a variety of serious and painful diseases.

But Desjardins is a credit union, with 250,000 members, and credit unions, rightly, take pride in their community support. Desjardins' own web site describes its function as "Money at the service of human development " and that its "commitment to individuals and communities is baerd on kindness and mutuall assistance "

I am not at all knowledgeable about trading and it may well be that these trading patterns do align with corporate values - but I'm puzzled.

Could someone put me right on this?
<< Previous
Bullboard Posts
Next >>